Conditions: Hepatitis C
Keywords: 7977 5885 GS-7977 GS-5885 SOF LDV Sofosbuvir Ledipasvir FDC
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 5
Healthy volunteers: no

Brief summary:
This study is to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with nosocomial genotype 1 hepatitis C virus (HCV) infection.

Detailed description:

Arms:
arm 1: Participants will receive LDV/SOF FDC for 12 weeks.

Interventions: intervention 1: LDV/SOF
Intervention descriptions: intervention 1: Ledipasvir (LDV)/sofosbuvir (SOF) 90/400 mg FDC tablet administered orally once daily

Protocol document: